Diopsys, Inc.

PINE BROOK,  NJ 
United States
http://www.diopsys.com
  • Booth: 813


World Leader in Modern Visual Electrophysiology

We help eye care specialists detect dysfunction early, track disease progression, and tailor treatment using objective results of visual function.

As the world leader in modern visual electrophysiology, Diopsys has done more than any other company to advance the use of electroretinography (ERG) and visual evoked potential (VEP) in the eye care practice. Performing these tests allow you to objectively evaluate retinal and visual pathway health now and over time for more precise disease management.

Brands: Light Induced Visual-response (LIV)™ Detect early. Track progression. Tailor treatment. That's LIV-ing. Performing LIV tests allow you to objectively evaluate retinal and visual pathway health now and over time for early detection, tailored treatment, and more precise disease management.


 Show Specials

  • Special Show Pricing

    Stop by the Diopsys Booth and ask about our Special Show Pricing for the Diopsys® ffERG (full field electroretinography) module. A NEW vision test has just been added - the Diopsys® ffERG / Flash Plus Photopic Negative Response. This vision test provides objective information to help you evaluate optic nerve and retinal disease affecting retinal ganglion cell function, including glaucoma.*  More =>

    The Diopsys® ffERG module also includes the Diopsys® Chromatic Flash Vision Screener. Now you can quickly and easily screen patients with risk factors like diabetes, and counsel patients in the earliest stages of disease. More =>

    *Reference on file at Diopsys.com


 Press Releases

  • Diopsys® ffERG/Flash Plus Photopic Negative Response Launches to Eye Care Practices Globally

    Diopsys Inc, the world leader in modern visual electrophysiology, announces the release of the Diopsys® ffERG/Flash Plus Photopic Negative Response vision test, a new full field electroretinography (ffERG) protocol designed to detect early signs of glaucoma.1-6

    Diopsys Commitment to Early Glaucoma DetectionBy 2050, it is estimated that 6.3 million Americans will have glaucoma, with black Americans having the highest prevalence rate. This disease can lead to irreversible vision loss and blindness, but with timely treatment, disease progression can be slowed. Since there is no cure for glaucoma, early detection is a key factor in preventing loss of sight.

    No single test detects glaucoma, as the disease is diagnosed through a comprehensive eye exam that includes several different tests to help build a clinical picture. Unfortunately, sensitive indicators of early glaucoma are difficult to discern, and results from various tests can be equivocal or unreliable.

    The new Diopsys® ffERG / Flash Plus Photopic Negative Response (PhNR) vision test fills a diagnostic need by providing doctors objective information on the function of retinal ganglion cells (RGCs) and their axons.1 RGCs are the neurons that link the eye to the brain and are the cells primarily damaged by glaucoma. Through evaluating how these cells are functioning, Diopsys® ffERG / Flash Plus PhNR results can provide information on “stressed” cells at a subclinical stage, when they have become dysfunctional but are still alive. Eye care professionals can then begin treatment at this early stage, slowing the progression of the disease, and preserving sight for their patients.

    “We are committed to helping the eye care community diagnose glaucoma as early as possible, ” said Alberto González García, MD, Chief Medical Officer at Diopsys. “This new ffERG test provides clinicians with a way to objectively evaluate RGC function efficiently in their practices to make the best clinical decisions for their patients.”

    Diopsys also offers another objective test of RGC function called pattern electroretinography (PERG). PERG has been shown to detect RGC dysfunction up to 8 years before changes in RNFL thickness as shown on OCT.7 Both PERG and ffERG/Flash Plus PhNR tests are clinically suitable to evaluate retinal ganglion cell dysfunction and can help eye care professionals in the decision to initiate treatment. The new Diopsys® ffERG / Flash Plus PhNR test has several testing advantages, including the ability to test in a lit room with no refraction needed.

    Diopsys plans to showcase Diopsys® ffERG / Flash Plus Photopic Negative Response at several upcoming eye care conferences. For more information, visit Diopsys.com/PhNR.

    1. Frishman L, et al. ISCEV extended protocol for the photopic negative response (PhNR) of the full-field electroretinogram. Doc Ophthalmol. 2018;136:207-211. 2. North RV, et al. Electrophysiological Evidence of Early Functional Damage in Glaucoma and Ocular Hypertension. Invest. Ophthalmol. Vis. Sci. 2010;51(2):1216-1222. 3. Viswanathan S, et al. The Photopic Negative Response of the Flash Electroretinogram in Primary Open Angle Glaucoma. Invest. Ophthalmol. Vis. Sci. 2001;42(2):514-522. 4. Machida S, et al. Photopic negative response of focal electoretinograms in glaucomatous eyes. Invest Ophthalmol Vis Sci. 2008;49:5636-44. 5. Gotoh Y, et al. Selective loss of the photopic negative response in patients with optic nerve atrophy. Arch Ophthalmol. 2004;122:341–346. 6. Miyata K, et al. Reduction of oscillatory potentials and photopic negative response in patients with autosomal dominant optic atrophy with OPA1 mutations. Invest Ophthalmol Vis Sci. 2007;48:820–824. 7. Banitt MR, et al. Progressive Loss of Retinal Ganglion Cell Function Precedes Structural Loss by Several Years in Glaucoma Suspects. Invest. Ophthalmol. Vis. Sci. 2013;54(3):2346-2352.

  • The Diopsys® Chromatic Flash Vision Screener is a simple-to-use and easy-to-integrate protocol within the Diopsys® ffERG / Full Field Electroretinography module.

    Diopsys Inc, the world leader in modern visual electrophysiology, announces the release of the Diopsys® Chromatic Flash Vision Screener, a new screening protocol designed to detect early retinal function changes in patients with diabetes.

    Recent epidemiologic data suggest that the prevalence of diabetes has increased significantly over the past two decades and that it will continue to rise in the future. Although it is commonly associated with systemic complications, diabetes can also affect the blood vessels in the eye leading to increased vascular permeability, putting patients at risk for developing microaneurysms, hemorrhages and hard exudates. The more advanced stages of diabetic retinopathy (DR) are associated with fibrosis and retinal ischemia, which may lead to the development of neovascularization.

    Fortunately, evolving treatment standards in DR have proven highly successful at arresting the disease process, but intervention is most successful when the disease is caught early. Recognizing the signs on clinical examination or with imaging, however, is challenging, and many cases are identified only after permanent damage has occurred.

    Diopsys Chromatic Flash Vision Screener_Dr. LighthizerThe Diopsys® Chromatic Flash Vision Screener helps address the unmet need for early recognition of retinal function changes related to DR with this new easy-to-use in-office screening test. Using red-on-blue flash electroretinography (ERG), the Diopsys® Chromatic Flash Vision Screener records the electrical potential of the retina to provide quantitative measurements of retinal function. Results are then analyzed against healthy reference range data to help the doctor understand the probability of the patient developing retinopathy. The protocol is part of the Diopsys® ffERG / Full Field Electroretinography module and is compatible with all new Diopsys® platforms.

    “The Diopsys Chromatic Flash Vision Screener is an exciting advancement in patient care that allows non-dilated testing of diabetic patients to help screen for the earliest signs of pathology. In diabetic retinopathy, we know functional changes will likely happen before structural changes, and to now have the ability to measure retinal function via this new test from Diopsys is truly a game changer,” said Nate Lighthizer, OD, FAAO. “It has been very useful as a screening test in our diabetic patients without retinopathy to help guide our management options and follow-up based on the results. The OCT, a structural test, has been utilized as a screener for some time, and this new test from Diopsys brings us the ability to also use function as a risk indicator.”


 Products

  • Diopsys® NOVA™, ARGOS™ and RETINA PLUS™
    The Diopsys® NOVA™ (cart), Diopsys® ARGOS™ (tabletop), and the NEW Diopsys® RETINA PLUS™ (carry case) ERG and VEP Vision Testing Systems allow you to perform multiple visual electrophysiology tests right in your clinical practice....

  • Three platforms. Complete visual electrophysiology suite.

    We understand that not all eye care practices are the same. Therefore, we provide three unique platforms for our advanced suite of visual electrophysiology modules. The Diopsys® NOVA™ (cart), Diopsys® ARGOS™ (tabletop), and the NEW Diopsys® RETINA PLUS (carry case) ERG and VEP Vision Testing Systems allow you to perform multiple visual electrophysiology tests right in your clinical practice.


Send Email

Type your information and click "Send Email" to send an email to this exhibitor. To return to the previous screen without saving, click "Reset".


For Technical Support with this webpage, please contact support.